Hansa Biopharma AB (HNSBF) Q4 2024 Earnings Call Transcript

2025-02-06 13:13:06 ET

Hansa Biopharma AB (HNSBF)

Q4 2024 Earnings Conference Call

February 6, 2025 08:00 AM ET

Company Participants

Soren Tulstrup - President and CEO

Evan Ballantyne - Chief Financial Officer

Hitto Kaufmann - Chief R&D Officer

Conference Call Participants

Suzanne van Voorthuizen - Kempen

Alexander Kramer - ABG

Douglas Tsao - H.C. Wainwright

Eric Young - William Blair

Johan Unnerus – Redeye

Presentation

Operator

Good day, and welcome to the Hansa Biopharma Year End and Fourth Quarter 2024 Report. All participants will be in listen-only mode. [Operator Instructions] After today’ s presentation there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Soren Tulstrup, President and CEO. Please go ahead.

Soren Tulstrup

Thank you, operator. Good afternoon, good morning, and welcome to the Hansa Biopharma conference call to review the full-year and Q4 results for 2024. I'm John Tulloch, President and CEO of Hansa Biopharma. Joining me today is Evan Ballanti-ne, Chief Financial Officer and Hitto Kaufmann, Chief R&D Officer.

Please turn to Slide 2. Please allow me to draw your attention to the fact that we will be making forward-looking statements during this presentation, and you should therefore apply appropriate caution....

Read the full article on Seeking Alpha

For further details see: